Can You Take Thymosin Alpha-1 With Tirzepatide or Semaglutide?

Every figure is an all-in monthly price covering medication, physician review, refill management and shipping, with no separate membership fee. Pepti is cash-pay and does not bill insurance. Current pricing always lives on each product page.

• No trial has tested the combination. The evidence for each belongs to that medication alone, and thymosin alpha-1's trials were in people with hepatitis, sepsis or cancer.
• No interaction has been described. There is no established interaction list for thymosin alpha-1, which is why the intake asks for every medication you take.
• Thymosin alpha-1 is injected, so gastric emptying is not the issue. GLP-1 medications slow gastric emptying, which can change how oral medications are absorbed. That does not apply to a subcutaneous injection.
• Its safety record is long but disease-based. Its randomised trials, including a 1,106-patient sepsis trial published in the BMJ in 2025, report adverse-event rates similar to placebo. There are no randomised trials in otherwise healthy adults, and no data at all with a GLP-1.

This pairing is unusual because the two side-effect profiles barely touch.

Thymosin alpha-1 does not produce a felt effect, and noticing nothing is normal. So if stomach symptoms, tiredness or headache appear in the weeks after starting both, the GLP-1 and its dose steps are the first place to look, along with meals and fluids. GLP-1 nausea: how to manage it covers what helps, and the full list is in GLP-1 side effects. Starting the two on different dates still makes the picture clearer.

For swelling of the face, lips or throat, widespread hives, trouble breathing, chest pain or fainting, call 911 first. If you think you injected far more than your directions, call Poison Control at 1-800-222-1222 and message your care team.

None of these changes because of a GLP-1, but all of them go on the same intake. The wider category is in peptides for immune support.

FORTIFY carries thymosin alpha-1 with BPC-157, KPV and LL-37, and the points above apply to its thymosin alpha-1 component. People sometimes ask whether the BPC-157 in it helps with tirzepatide's stomach side effects. Nausea, reflux and constipation on a GLP-1 are a dose and titration question for the prescribing physician, not a reason to add a second vial, and BPC-157 is not a treatment for GLP-1 side effects. FORTIFY's directions are printed on the vial. More is in what is the FORTIFY blend.

Everything above applies to semaglutide, which acts at one incretin receptor where tirzepatide acts at two. Neither shares a pathway with thymosin alpha-1. Semaglutide and tirzepatide are never taken together. The full comparison is in semaglutide vs tirzepatide.

1. Name the reason. What you want help with, and any immune condition you have, gives your physician more to work with than a product name.
2. List everything at intake, including any immunosuppressant, any cancer treatment, any diagnosed infection and every blend you already take.
3. Start one thing at a time, away from a GLP-1 dose step.
4. Follow each label separately. At Pepti's typical directions, the thymosin alpha-1 vial is 0.25 mL (25 units) under the skin once daily Monday through Friday, 0.5 mg per dose from the 2 mg/mL vial, 20 doses per vial, about four weeks. The Pen is dosed by dial, as printed with your prescription. Tirzepatide and semaglutide are once weekly. Never mix vials in one syringe.
5. Report what happened, including nothing. With thymosin alpha-1, nothing is the usual experience.

Your physician sets your directions after reviewing your intake, and every vial arrives with its directions printed on the label. The wider pairing picture is in what peptides can you take with tirzepatide, and the general principles in can you take two peptides together.

Tirzepatide and semaglutide have a very large human evidence base in their branded forms. Thymosin alpha-1 has one of the longest human safety records of any compounded peptide: randomised trials in hepatitis B, hepatitis C, sepsis and melanoma, the largest a 1,106-patient double-blind trial, all reporting it as well tolerated. Those trials were in sick populations, the compounded weekday schedule differs from the branded product's labelled 1.6 mg twice weekly, and no trial has combined it with a GLP-1. What can be said is narrow: unrelated systems, no described interaction, and side-effect profiles that barely overlap.

On 4 December 2024 the FDA's Pharmacy Compounding Advisory Committee voted 4 to 17 against adding thymosin alpha-1 to the 503A Bulks List, citing insufficient characterisation, safety information including immunogenicity, and effectiveness evidence. That vote is a recommendation, and the FDA has not issued a final determination; on the interim list updated 14 May 2026 it does not appear in Category 1, 2 or 3. The immunogenicity concern is about aggregated or impure material, which is why the source of a compounded peptide matters. Compounded medications are not FDA approved. Compounded tirzepatide and semaglutide are the same active ingredients as the branded products, and the trial data belongs to the manufactured products. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.

1. Complete a free online intake covering your history, medications, immune conditions and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares each prescription. Lot test results are published at /quality/lab-results.
4. Each vial ships refrigerated with ice packs, with sterile syringes and alcohol prep pads, and its directions printed on the vial.
5. Refills run every 28 days, one vial per fill, and your care team stays reachable for questions and side effects.

Step by step: how to get thymosin alpha-1 prescribed online, how to get tirzepatide prescribed online and how to get semaglutide prescribed online.